Vaxcyte, Inc. – NASDAQ:PCVX

Add to watchlist

$31.73

-49.23

-60.81%

Market closed

Open in about 13 hours

-1.72%

month

-1.72%

quarter

+27.69%

year

Market Cap	10.81B
Enterprise value	1.43B

P/E	-10.05
EV/Sales	N/A
EV/EBITDA	-6.94
Price/Sales	N/A
Price/Book	2.35
PEG ratio	0.12
EPS	-4.36

Revenue	N/A
EBITDA	-406.5M
Income	-436.82M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Vaxcyte Stock Forecast

M Q Y

Last Year

$137.44

Potential upside: 333.16%

Analysts Price target
Financials & Ratios estimates

Vaxcyte, Inc. (NASDAQ:PCVX): Profit margin
Jun 2023	0	-68.33M
Sep 2023	0	-92.66M
Dec 2023	14.44M	-180.80M	-1251.56%
Mar 2024	0	-95.02M

Vaxcyte, Inc. (NASDAQ:PCVX): Debt to assets
Jun 2023	1502819000	69.44M	4.62%
Sep 2023	1496057000	93.34M	6.24%
Dec 2023	1407917000	167.44M	11.89%
Mar 2024	2091305000	107.32M	5.13%

Vaxcyte, Inc. (NASDAQ:PCVX): Cash Flow
Jun 2023	-62.74M	-333.56M	546.96M
Sep 2023	-57.54M	22.28M	48.55M
Dec 2023	-128.81M	-13.92M	2.73M
Mar 2024	-159.12M	-451.07M	818.19M

Vaxcyte alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Vaxcyte, Inc. (NASDAQ:PCVX): Employee count
Aug 2023	158
Sep 2023	158
Oct 2023	158
Nov 2023	158
Dec 2023	158
Jan 2024	158
Feb 2024	158
Mar 2024	254
Apr 2024	254
May 2024	254
Jun 2024	254
Jul 2024	254

Vaxcyte
Hedge Funds Holdings Q1 2023

51.85% -48.15%

of PCVX is owned by hedge funds

96 -101

hedge funds hold PCVX stock

33.63M -47.90M

shares is hold by hedge funds

PCVX hedge funds holdings changes

Vaxcyte, Inc. (NASDAQ:PCVX): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	53000
Mar 2024	0	41961
Apr 2024	0	30283
May 2024	0	30283
Jun 2024	0	48483
Jul 2024	0	12283
Oct 2024	0	109098
Nov 2024	0	38250
Dec 2024	0	30366

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	9 Dec 2024	PICKERING GRANT director, officer..	Common Stock	961	$92.06	$88,470
Sale	9 Dec 2024	PICKERING GRANT director, officer..	Common Stock	1,029	$92.03	$94,701
Sale	9 Dec 2024	PICKERING GRANT director, officer..	Common Stock	376	$93.35	$35,099
Option	5 Dec 2024	EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & CORP SEC officer: SVP, GEN COUNSEL & COR..	Stock Option (right to buy)	5,000	$21.41	$107,050
Option	5 Dec 2024	EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & CORP SEC officer: SVP, GEN COUNSEL & COR..	Common Stock	5,000	$21.41	$107,050
Sale	5 Dec 2024	EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & CORP SEC officer: SVP, GEN COUNSEL & COR..	Common Stock	1,435	$90.16	$129,384
Sale	5 Dec 2024	EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & CORP SEC officer: SVP, GEN COUNSEL & COR..	Common Stock	3,177	$91.91	$292,004
Sale	5 Dec 2024	EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & CORP SEC officer: SVP, GEN COUNSEL & COR..	Common Stock	388	$92.9	$36,046
Sale	2 Dec 2024	PICKERING GRANT director, officer..	Common Stock	11,349	$92.06	$1,044,789
Sale	2 Dec 2024	PICKERING GRANT director, officer..	Common Stock	1,409	$93.06	$131,123

Vaxcyte
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q4 2022 27 Feb 2023	Q4 2022 Earnings Call Transcript
Q4 2021 28 Feb 2022	Q4 2021 Earnings Call Transcript
Q4 2020 29 Mar 2021	Q4 2020 Earnings Call Transcript

PCVX earnings call transcripts

Vaxcyte
Executives

Insider	Age	Compensation
Mr. Grant E. Pickering (1968) Co-Founder, Chief Executive Officer & Director	57	$750,920
Mr. James Wassil M.B.A., M.S. (1969) Chief Operating Officer	56	$651,060
Mr. Andrew L. Guggenhime M.B.A. (1968) Pres & Chief Financial Officer	57	$540,710

Vaxcyte
Latest News

Thursday, 19 December 2024
12:16	Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm	globenewswire.com
Tuesday, 3 December 2024
08:00	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants	globenewswire.com
Tuesday, 12 November 2024
07:30	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs	globenewswire.com
Tuesday, 5 November 2024
16:01	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Wednesday, 11 September 2024
16:05	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference	globenewswire.com
Sunday, 8 September 2024
09:00	Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027	seekingalpha.com
Friday, 6 September 2024
16:05	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares	globenewswire.com
15:07	Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy	seekingalpha.com
09:07	Vaxcyte's stock dips after biotech completes $1.42 billion stock offering	marketwatch.com
Thursday, 5 September 2024
01:22	Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high	reuters.com
Wednesday, 4 September 2024
23:58	Vaxcyte Announces Pricing of $1.3 Billion Public Offering	globenewswire.com
11:56	Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results	zacks.com
Tuesday, 3 September 2024
16:01	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants	globenewswire.com
14:10	Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower	schaeffersresearch.com
10:48	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.	barrons.com
09:24	Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine	reuters.com
09:07	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market	investors.com
08:51	Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine	marketwatch.com
07:07	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older	globenewswire.com
Monday, 2 September 2024
18:40	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older	globenewswire.com
Monday, 26 August 2024
13:30	SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)	prnewswire.com
Wednesday, 31 July 2024
10:56	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?	zacks.com
Monday, 29 July 2024
13:00	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice	zacks.com
Tuesday, 2 July 2024
08:30	Vaxcyte Appoints John Furey to Board of Directors	globenewswire.com
Wednesday, 8 May 2024
16:05	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Tuesday, 2 April 2024
16:05	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	GlobeNewsWire
Wednesday, 28 February 2024
13:01	Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know	Zacks Investment Research
Monday, 26 February 2024
09:36	Why Vaxcyte (PCVX) Might Surprise This Earnings Season	Zacks Investment Research
08:41	5 Stocks to Buy That Are Poised to Beat on Earnings This Week	Zacks Investment Research
Thursday, 15 February 2024
16:05	Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 15 Jan 2025

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Seeking Alpha 16 Oct 2023

Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling
Seeking Alpha 14 Sep 2023

Sutro BioPharma: Good Stewardship Through Early Trials
Seeking Alpha 17 Aug 2023

Strong Financials And Pipeline Position Vaxcyte For Success
Seeking Alpha 17 May 2023

Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential
Seeking Alpha 19 Jan 2023

Vir Biotechnology: High Potential Returns With High Volatility Risks
Seeking Alpha 2 Nov 2022

Vaxcyte Has A Bright Future Ahead
Seeking Alpha 27 Dec 2021

Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Seeking Alpha 27 Jun 2021

Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An Edge

Frequently Asked Questions (FAQ)

What's the price of Vaxcyte stock today?

One share of Vaxcyte stock can currently be purchased for approximately $31.73.
When is Vaxcyte's next earnings date?

Unfortunately, Vaxcyte's (PCVX) next earnings date is currently unknown.
Does Vaxcyte pay dividends?

No, Vaxcyte does not pay dividends.
How much money does Vaxcyte make?

Vaxcyte has a market capitalization of 10.81B.
What is Vaxcyte's stock symbol?

Vaxcyte, Inc. is traded on the NASDAQ under the ticker symbol "PCVX".
What is Vaxcyte's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Vaxcyte?

Shares of Vaxcyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Vaxcyte's key executives?
Vaxcyte's management team includes the following people:
- Mr. Grant E. Pickering Co-Founder, Chief Executive Officer & Director(age: 57, pay: $750,920)
- Mr. James Wassil M.B.A., M.S. Chief Operating Officer(age: 56, pay: $651,060)
- Mr. Andrew L. Guggenhime M.B.A. Pres & Chief Financial Officer(age: 57, pay: $540,710)
Is Vaxcyte founder-led company?

Yes, Vaxcyte is a company led by its founder Mr. Grant E. Pickering.
How many employees does Vaxcyte have?

As Jul 2024, Vaxcyte employs 254 workers.
When Vaxcyte went public?

Vaxcyte, Inc. is publicly traded company for more then 5 years since IPO on 12 Jun 2020.
What is Vaxcyte's official website?

The official website for Vaxcyte is vaxcyte.com.
Where are Vaxcyte's headquarters?

Vaxcyte is headquartered at 825 Industrial Road, San Carlos, CA.
How can i contact Vaxcyte?

Vaxcyte's mailing address is 825 Industrial Road, San Carlos, CA and company can be reached via phone at +65 08370111.
What is Vaxcyte stock forecast & price target?

Based on 5 Wall Street analysts` predicted price targets for Vaxcyte in the last 12 months, the avarage price target is $137.44. The average price target represents a 333.16% change from the last price of $31.73.

Vaxcyte, Inc.

vaxcyte.com

Exchange:

NASDAQ

Full time employees:

254

Industry:

Biotechnology

Sector:

Healthcare

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

+65 08370111

825 Industrial Road
San Carlos, CA 94070

CIK: 0001649094
ISIN: US92243G1085
CUSIP: 92243G108